Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)
- Expansion demonstrates company's commitment to innovation and
leadership in global public health
- New Toronto facility is one of
the largest-ever investments by Sanofi in a single building
- Significantly increases capacity to meet growing demand for
pediatric and booster vaccines
TORONTO, April 12, 2018 /CNW Telbec/ - Sanofi is investing
€350 million (CAD $500 million) for
the construction of a new state-of-the-art vaccine manufacturing
facility at the Sanofi Pasteur Canadian headquarters in
Toronto, Ontario. The investment
bolsters the company's Canadian operations and its commitment to
advancing public health around the world.
The announcement will be made during an event today at Sanofi
Pasteur's Toronto facility.
Attendees will include the Honourable Navdeep Bains, Minister of
Innovation, Science and Economic Development, Government of
Canada, the Honourable Steven Del
Duca, Minister of Economic Development and Growth, Government of
Ontario, and members of Sanofi's
executive leadership.
"Canada has a strong legacy
in the research and development of vaccines. With this investment,
Sanofi is renewing our longstanding commitment to making
Canada central in our effort to
protect and improve human health across the globe," said
David Loew, Executive Vice President
and Head of Sanofi Pasteur. "Vaccines save three million lives
every year and this new facility will take us one step closer to a
world where no one suffers or dies from a vaccine-preventable
disease."
The new facility will allow Sanofi Pasteur, the vaccines global
business unit of Sanofi, to meet the growing demand of
five-component acellular pertussis (5-acP) antigen. Upon completion
in 2021, the new building will also be equipped to produce the
antigens used in the diphtheria and tetanus vaccines.
"This project is one of the most important investments for
the Sanofi global industrial network," said Philippe Luscan, Executive Vice President,
Global Industrial Affairs, Sanofi. "It demonstrates our
continued commitment to manufacturing excellence and to better
serving our vaccines portfolio to people all over the
world."
About the Sanofi Pasteur Canadian Facilities
Founded as the Connaught Antitoxin Laboratories and University
Farm in 1917, Sanofi Pasteur's Canadian facility has supported
numerous scientific breakthroughs while making significant public
health contributions. The Toronto
site was home to the world's first large-scale commercial insulin
production and was the sole supplier of the diabetes treatment to
Canadians until the 1980s. It also produced a highly accessible
antitoxin for diphtheria, the leading public health threat to
Canadian children in the early 1900s, and was an important partner
in the eradication of polio in North
America and smallpox around the world.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Sanofi Forward-Looking Statements
This press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with
intellectual property and any related pending or future litigation
and the ultimate outcome of such litigation, trends in exchange
rates and prevailing interest rates, volatile economic conditions,
the impact of cost containment initiatives and subsequent changes
thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
SOURCE Sanofi Canada